Press Releases Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 18:02:01 10/04/2026 BST			5-day change	1st Jan Change
941.04 ^USD	-1.48%		+1.42%	-12.51%

01:44pm	Wall Street Gets a CPI Lifeline
01:43pm	LifeMD Now Offers Eli Lilly's Foundayo to Eligible Patients Through its Weight Management Program	MT

Press Releases

04:29pm	Amazon Pharmacy to Offer Eli Lilly and Company's New GLP-1 Pill Foundayo via Same-Day Delivery	AQ
03:27pm	GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo, and Zepbound KwikPen with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide	AQ
04-09	Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.	PR
04-08	Eli Lilly and : 2026 Estimated Acquired IPR&D And Development Milestone Charges for Q1 2026	PU
04-01	FDA approves Eli Lilly's GLP-1 weight-loss pill	AQ
04-01	FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity	AQ
04-01	FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions	PR
03-30	Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis	AQ
03-30	Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz plus Zepbound delivered superior efficacy for adults with psoriatic arthritis and obesity	AQ
03-30	TGFB Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook	AQ
03-28	Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity	PR
03-27	AAD 2026: Almirall Presents New Clinical and Real-world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne	AQ
03-27	Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis	PR
03-22	Pharmaceutical firm Eli Lilly invests 3 billion dollars in China for slimming drug	AQ
03-19	Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes	PR
03-16	Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis	PR
03-13	Indiana Sues Eli Lilly Over Skyrocketing Insulin Prices	AQ
03-12	Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect	PU
03-12	Andel Launches New Direct-to-Employer Medication Platform to Make GLP-1s Affordable for Millions	AQ
03-12	Eli Lilly and : An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12	PU
03-11	Samsung, Eli Lilly launch South Korea biotech innovation hub	AQ
03-09	Eli Lilly and : Lilly’s statement on the CMMI BALANCE Model for GLP-1 medicines	PU
03-05	Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients	PR
03-02	Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata	AQ
02-26	Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet	PR